Alarum Faces Securities Probe Amid Margin and Concentration Concerns

What happened

On July 8, 2026, Rosen Law Firm announced an investigation into Alarum Technologies for possibly issuing materially misleading business information to investors. This legal development adds a layer of uncertainty to a company already grappling with significant operational challenges: FY2025 gross margin collapsed to 58.5% from 75.1% as scaling costs surged, net retention fell to 0.83, and top-6 customers now account for ~49% of revenue. Alarum’s stock, which had already fallen from highs above $17 to $7.90, faces renewed pressure as the probe threatens to distract management and potentially lead to costly litigation. The company’s cash balance of $22.5M provides a cushion, but combined with the existing bear case—AI workload volatility, margin compression, and concentration risk—this investigation makes the risk/reward even less favorable for current holders.

Implication

Investors should avoid ALAR until there is clarity on the investigation's outcome, as even if the claims are unfounded, the distraction and legal costs could delay margin improvement and strategic execution. The existing thesis—which already called for a wait stance due to margin and concentration issues—now has an added legal overhang. Only consider re-entry if the investigation is quickly resolved without material penalty AND Q1-Q2 2026 results show gross margin above 62% with declining third-party costs, indicating the core business is healing. Until then, downside risks outweigh upside potential.

Thesis delta

The launch of a securities investigation materially increases the risk profile for ALAR, shifting the thesis from 'wait for margin improvement' to 'avoid until legal overhang clears.' The probability of the bear scenario (30%, $6.00) has increased as the investigation could amplify customer attrition, management distraction, and cost risk. Our existing 'What Changes The Call' conditions remain valid but now require additional filter: resolution of the investigation without material adverse finding. The conviction on the 'Wait' rating is reduced, and the attractive entry of $6.50 may need to be re-evaluated lower to reflect this added risk.